Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PFE vs. RHHBY: Which Stock Is the Better Value Option?

Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.

Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung

by Zacks Equity Research

Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.

Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag

by Zacks Equity Research

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA

by Zacks Equity Research

Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.

Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%

by Zacks Equity Research

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

by Zacks Equity Research

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Mark Vickery headshot

Top Research Reports for Berkshire Hathaway, Thermo Fisher & salesforce

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Thermo Fisher Scientific Inc. (TMO), and salesforce.com, inc. (CRM).

Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022

by Zacks Equity Research

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.

Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod

by Zacks Equity Research

Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.

Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq

by Zacks Equity Research

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche

by Zacks Equity Research

Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.

Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA

by Zacks Equity Research

The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.

Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19

by Zacks Equity Research

The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.

    Novartis (NVS) Highlights Growth Profile at its R&D Day

    by Zacks Equity Research

    Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

    Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.

    ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study

    by Zacks Equity Research

    ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

    4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

    by Zacks Equity Research

    Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

    Kinjel Shah headshot

    Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids

    by Kinjel Shah

    FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.

    Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU

    by Zacks Equity Research

    Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.